Compare FSI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | KPTI |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.6M | 94.6M |
| IPO Year | 1999 | 2013 |
| Metric | FSI | KPTI |
|---|---|---|
| Price | $6.86 | $5.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 56.4K | ★ 114.4K |
| Earning Date | 11-14-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | $38,563,427.00 | ★ $142,530,000.00 |
| Revenue This Year | $8.45 | $3.82 |
| Revenue Next Year | $51.24 | $3.18 |
| P/E Ratio | $49.13 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $3.46 | $3.51 |
| 52 Week High | $11.48 | $12.45 |
| Indicator | FSI | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 50.33 |
| Support Level | $6.35 | $5.30 |
| Resistance Level | $7.13 | $6.05 |
| Average True Range (ATR) | 0.43 | 0.44 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 32.90 | 37.50 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.